DICE Therapeutics, Inc.
DICEDelisted Aug 9, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001645569
DICE Therapeutics, Inc. was delisted on Aug 9, 2023; its insiders filed their last Form 4 on Aug 9, 2023; 160 institutions reported holding it in 13F filings for Q2 2023, worth $2.12B in total; Fairfax Financial was the only superinvestor holding it.
Q3 2022 vs. Q2 2022
How the institutions holding DICE Therapeutics, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Of which not filed for Q3 2022 | Q3 2022 | Change |
|---|---|---|---|---|
| Holders | 80 | 1 | 79 | 0 |
| Shares | 36.4M | 89 | 36.9M | +478.1K (+1.3%) |
| Value | $564.6M | $1.00K | $748.2M | +$183.5M (+32.5%) |
1 institution that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (12)
Institutions that held DICE Therapeutics, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| VR Adviser, LLC | 764,979 | $15.5M | 2.39% |
| Sphera Funds Management Ltd. | 152,913 | $3.10M | 0.55% |
| Nicholas Investment Partners, LP | 97,838 | $1.98M | 0.18% |
| Parallax Volatility Advisers, L.P. | 71,779 | $1.46M | 0.03% |
| Group One Trading, L.P. | 13,871 | $281.0K | 0.01% |
| Mirae Asset Global Investments Co., Ltd. | 11,807 | $239.0K | 0.00% |
| Ensign Peak Advisors, Inc | 11,177 | $227.0K | 0.00% |
| Graham Capital Management, L.P. | 10,171 | $206.0K | 0.01% |
| Chicago Partners Investment Group LLC | 6,588 | $204.0K | 0.01% |
| Acuta Capital Partners, LLC | 6,700 | $136.0K | 0.06% |
| UBS Group AG | 123 | $2.00K | 0.00% |
| Nisa Investment Advisors, LLC | 23 | $1.00K | 0.00% |
Sold out (12)
Institutions that held DICE Therapeutics, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Eventide Asset Management, LLC | 1,370,261 | $20.8M |
| Ally Bridge Group (NY) LLC | 207,290 | $3.22M |
| First Manhattan Co | 155,904 | $2.42M |
| Ghost Tree Capital, LLC | 30,000 | $466.0K |
| Voloridge Investment Management, LLC | 25,692 | $399.0K |
| Qube Research & Technologies Ltd | 17,903 | $278.0K |
| Gsa Capital Partners LLP | 13,325 | $207.0K |
| Tudor Investment Corp Et Al | 12,369 | $192.0K |
| SG Americas Securities, LLC | 8,429 | $131.0K |
| Simplex Trading, LLC | 7,277 | $112.0K |
| State of Wyoming | 50 | $1.00K |
| Ronald Blue Trust, Inc. | 13 | $0 |
Not filed for Q3 2022 yet (1)
Institutions that held DICE Therapeutics, Inc. at the end of Q2 2022 and haven't filed a 13F for Q3 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Private Capital Group, LLC | 89 | $1.00K |